It has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new share buyback program.
Key Takeaways
- The timing of the buyback is interesting as it comes as Genmab gets into a legal spat with partner AbbVie
- Genmab is confident that a
Under the plan, the Copenhagen-headquartered firm may repurchase up to 2.2 million shares with a maximum value of DKK4.0bn ($578.5m)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?